Market Place
Sourcing Support
Novartis, Apellis roll out rival datasets in rare kidney disease
28 Oct 2024 //
FIERCE PHARMA
Apellis To Host Q3 2024 Results Conference Call On Nov 5
22 Oct 2024 //
GLOBENEWSWIRE
Apellis Presents Phase 3 VALIANT Study At ASN Kidney Week
16 Oct 2024 //
GLOBENEWSWIRE
Apellis Pharma Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
GLOBENEWSWIRE
Apellis To Host Fireside Chat At UBS Ophthalmology Day
25 Sep 2024 //
GLOBENEWSWIRE
Apellis hit with yet another eye drug snub in Europe
20 Sep 2024 //
FIERCE PHARMA
Apellis Receives Negative CHMP Opinion for Pegcetacoplan
20 Sep 2024 //
GLOBENEWSWIRE
Sobi And Enable Injections Partner On Aspaveli® With enFuse® Delivery
12 Sep 2024 //
GLOBENEWSWIRE
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
GLOBENEWSWIRE
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Sobi And Apellis Report Positive Results From Pegcetacoplan Study
09 Aug 2024 //
PR NEWSWIRE
Apellis Pharma Announces Inducement Grants Under Nasdaq Rule
06 Aug 2024 //
GLOBENEWSWIRE
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Apellis To Discuss Q2 2024 Results On August 1 Conference Call
18 Jul 2024 //
GLOBENEWSWIRE
Apellis To Present Five Oral Abstracts At ASRS Annual Meeting
09 Jul 2024 //
GLOBENEWSWIRE
EU`s drug regulator again rejects Apellis` eye med and PTC`s Translarna
02 Jul 2024 //
FIERCE PHARMA
Apellis Seeks Re-Examination Following Negative CHMP Opinion For Pegcetacoplan
28 Jun 2024 //
GLOBENEWSWIRE
SYFOVRE Preserved Vision In Geographic Atrophy Extension Study
10 Jun 2024 //
GLOBENEWSWIRE
MediciNova: Patent For MN-166 In Solid Cancer Metastasis Prevention
05 Jun 2024 //
GLOBENEWSWIRE
Pegcetacoplan 1-Year C3G Ic-Mpgn: Positive Post-Transplant Data At Era
24 May 2024 //
GLOBENEWSWIRE
Apellis takes it slow with first Syfovre DTC campaign
23 May 2024 //
FIERCE PHARMA
Apellis Refinances Debt With Up To $475M Facility From Sixth Street
14 May 2024 //
GLOBENEWSWIRE
Apellis`s Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit
14 May 2024 //
PRESS RELEASE
Apellis stock price slid 10% despite `robust` growth of Syfovre
09 May 2024 //
FIERCE PHARMA
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
07 May 2024 //
GLOBENEWSWIRE
Apellis To Host Fireside Chat At BofA Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Apellis: 11 Oral Presentations At ARVO Ophthalmology Meeting
01 May 2024 //
GLOBENEWSWIRE
Apellis: Pegcetacoplan MAA Review Reset by EMA
26 Apr 2024 //
GLOBENEWSWIRE
Apellis to Host Q1 2024 Financial Call on May 7
23 Apr 2024 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
GLOBENEWSWIRE
Apellis to Host a Fireside Chat at the 23rd Annual Virtual Healthcare Conference
01 Apr 2024 //
GLOBENEWSWIRE
Apellis Appoints Leading Expert Philip Ferrone as Chief Medical Retina Advisor
11 Mar 2024 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 //
GLOBENEWSWIRE
Apellis working through continued challenges with Syfovre launch
28 Feb 2024 //
FIERCE PHARMA
Apellis Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
26 Feb 2024 //
GLOBENEWSWIRE
Apellis to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 //
GLOBENEWSWIRE
Apellis Pharma Gets Negative CHMP Opinion for Intravitreal Pegcetacoplan
27 Jan 2024 //
PRESS RELEASE
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
08 Jan 2024 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
GLOBENEWSWIRE
Apellis to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Apellis to Host a Fireside Chat at Goldman Sachs Healthcare C-Suite Conference
28 Dec 2023 //
GLOBENEWSWIRE
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA
14 Dec 2023 //
GLOBENEWSWIRE
EMPAVELI Provided Long-Term Control of PNH in New Data Presented
11 Dec 2023 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Dec 2023 //
GLOBENEWSWIRE
Apellis Up 9.2% Since Last Earnings Report: Can It Continue?
01 Dec 2023 //
YAHOO FINANCE
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Conference
21 Nov 2023 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2023 //
GLOBENEWSWIRE
Apellis counters Izervay results with long-term data of its own
06 Nov 2023 //
FIERCE PHARMA
SYFOVRE Continued to ShowTreatment Effects Over 3 Years in Patients with GA
04 Nov 2023 //
GLOBENEWSWIRE
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Apellis to Host Conference Call to Discuss Third Quarter 2023 Financial Results
25 Oct 2023 //
GLOBENEWSWIRE
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE forGA
20 Oct 2023 //
GLOBENEWSWIRE
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan
17 Oct 2023 //
GLOBENEWSWIRE
Apellis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2023 //
GLOBENEWSWIRE
Apellis` stumbling GA drug Syfovre shows signs of recovery
05 Oct 2023 //
FIERCE PHARMA
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector
02 Oct 2023 //
GLOBENEWSWIRE
APLS Investors Have Opportunity to Lead Apellis Securities Fraud Lawsuit
29 Sep 2023 //
PR NEWSWIRE
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
27 Sep 2023 //
FOOL
